Flash VIG-news: Trisenox (arsenic trioxide): risk of medication errors due to the introduction of a new concentration of 2 mg/ml
Source: FAMHP
December 3, 2020
The FAMHP warns healthcare professionals prescribing, delivering and administering Trisenox about the risk of dosing errors as a new presentation of the medicine is launched on the market.
In 2019, the European Medicines Agency (EMA) recommended the approval of a new presentation of the injectable cancer medicine Trisenox (arsenic trioxide) that contains 2 mg/ml of the active substance in each vial. The new presentation will replace the existing one, which contains 1 mg/ml in each vial. In addition, the new vial contains a total volume of 6 ml (and a total content of 12 mg arsenic trioxide) whereas the existing vial contains 10 ml (and a total content of 10 mg arsenic trioxide).